Biotech Values

[biomaven0]

>>If enzalutamide extended the OS even a little bit, more patients in the enzalutamide arm were able to use cabazitaxel & abiraterone acetate

However, abiraterone after Xtandi failure is unlikely to do much at all. Abiraterone after placebo failure is likely to be very significant. That difference surely outweighs any small time advantage.

Peter